Clinical Research Directory

1. Subjects with Cerebral Venous Sinus Stenosis Inclusion Criteria: * Age ≥18 years, any gender; * Definite diagnosis of cerebral venous sinus stenosis confirmed by clinical and imaging examinations; * Stenosis limited to the transverse sinus and/or sigmoid sinus, presenting as moderate to severe localized stenosis or occlusion (stenosis degree ≥50%), with or without internal jugular vein stenosis; * The subject or their legal representative signs a written informed consent form. Exclusion Criteria: * Simple anatomical variation or physiological narrowing of the cerebral venous sinus/internal jugular vein without definitive evidence of localized stenosis; * Complicated by cerebral venous sinus/cortical vein/internal jugular vein thrombosis; * Prior receipt of endovascular treatment for cerebral venous sinus/internal jugular vein, ventricular puncture drainage, or lumbar cistern drainage before enrollment; * Presence of moderate to severe stenosis (≥50%) in intracranial or extracranial arteries; * History of cerebral infarction, cerebral hemorrhage, or neurosurgery; * Complicated by other neurological structural abnormalities such as cerebral small vessel disease, intracranial vascular malformation, dural arteriovenous fistula, intracranial infection, intracranial space-occupying lesion, severe cerebral atrophy, or hydrocephalus; * Presence of other diseases affecting glymphatic function (e.g., multiple sclerosis, neuromyelitis optica spectrum disorders, systemic lupus erythematosus, obstructive sleep apnea-hypopnea syndrome, Parkinson's disease, or Alzheimer's disease); * Contraindications to MRI (e.g., metal implants, claustrophobia, etc.) or allergy to gadolinium-based contrast agents; * Other conditions deemed unsuitable for enrollment by the investigator. 2. Subjects with Cerebral Venous Sinus Thrombosis Inclusion Criteria: * Age ≥18 years, any gender; * Definite diagnosis of acute or subacute phase (onset to diagnosis ≤28 days) cerebral venous sinus thrombosis, with or without internal jugular vein thrombosis, confirmed by clinical and imaging examinations; * The subject or their legal representative signs a written informed consent form. Exclusion Criteria: * Isolated cortical vein thrombosis or isolated cavernous sinus thrombosis; * Recurrent intracranial venous sinus thrombosis; * Complicated by venous cerebral infarction; * Prior receipt of endovascular treatment for cerebral venous sinus/internal jugular vein, ventricular puncture drainage, or lumbar cistern drainage before enrollment; * Presence of moderate to severe stenosis (≥50%) in intracranial or extracranial arteries; * History of cerebral infarction, cerebral hemorrhage, or neurosurgery; * Complicated by other neurological structural abnormalities such as cerebral small vessel disease, intracranial vascular malformation, dural arteriovenous fistula, intracranial infection, intracranial space-occupying lesion, severe cerebral atrophy, or hydrocephalus; * Presence of other diseases affecting glymphatic function (e.g., multiple sclerosis, neuromyelitis optica spectrum disorders, systemic lupus erythematosus, obstructive sleep apnea-hypopnea syndrome, Parkinson's disease, or Alzheimer's disease); * Presence of severe impaired consciousness, hearing impairment, or aphasia preventing cooperation with examinations or assessments; * Contraindications to MRI (e.g., metal implants, claustrophobia, etc.) or allergy to gadolinium-based contrast agents; * Other conditions deemed unsuitable for enrollment by the investigator. 3. Healthy Control Subjects: Inclusion Criteria: * Gender and age-matched; * No central nervous system diseases; * Normal scores on the HAMD-24, HAMA-14, MMSE, MoCA, and PSQI scales; * No cerebral venous sinus thrombosis, cerebral venous sinus stenosis, or moderate to severe intracranial/extracranial arterial stenosis; * No contraindications to MRI (e.g., metal implants, claustrophobia, etc.); * The subject or their legal representative signs a written informed consent form.